Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Delpazolid (LCB01-0371) Batches in Healthy Adults
NCT04939779Phase 1Completed
- Sponsor
- LigaChem Biosciences
- Start
- Jan 2021
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of delpazolid in Tuberculosis (TB) (2 arms), sponsored by LigaChem Biosciences. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to Last Measurable Concentration. Started Jan 2021; status: completed.
02
Drugs
delpazolid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04939779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939779.